IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11952347 B1

PDFFull Text
Date of Patent:
Apr. 09, 2024

Filed:

Dec. 01, 2021

Compounds and methods for the targeted degradation of androgen receptor

Applicant:

Arvinas Operations, Inc., New Haven, CT (US);

Inventors:

Andrew P. Crew, Chester, CT (US);

Lawrence B. Snyder, Killingworth, CT (US);

Jing Wang, Milford, CT (US);

Assignee:

Arvinas Operations, Inc., New Haven, CT (US);

Attorney:

COOLEY LLP

Primary Examiner:

Laura L Stockton

Int. Cl.
CPC ...
C07D 401/14 (2006.01); A61K 31/02 (2006.01); A61K 31/166 (2006.01); A61K 31/277 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); C07D 205/04 (2006.01); C07D 209/48 (2006.01); C07D 211/76 (2006.01); C07D 213/72 (2006.01); C07D 221/20 (2006.01); C07D 231/12 (2006.01); C07D 233/42 (2006.01); C07D 237/08 (2006.01); C07D 239/24 (2006.01); C07D 241/04 (2006.01); C07D 401/04 (2006.01);
U.S. Cl.
CPC ...
C07D 233/42 (2013.01); A61K 31/02 (2013.01); A61K 31/166 (2013.01); A61K 31/277 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); C07D 205/04 (2013.01); C07D 209/48 (2013.01); C07D 211/76 (2013.01); C07D 213/72 (2013.01); C07D 221/20 (2013.01); C07D 231/12 (2013.01); C07D 237/08 (2013.01); C07D 239/24 (2013.01); C07D 241/04 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01);
Abstract

The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

Find Patent Forward Citations

Loading…